Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008 Jun;117(25):e510-526.
The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. Semin Nephrol 2014 May;34(3):247-256.
Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015 Sep;36(33):2219-2227.
Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens 2016 Feb;30(2):83-89.
Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995 Jul;311(7000):293-295.
Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013 Dec;31(12):2455-2461.
Renal denervation for the management of resistant hypertension. Integr Blood Press Control 2015 Dec;8:57-69.
Renal sympathetic denervation— a review of applications in current practice. Interv Cardiol Rev 2014;9(1):54-61.
The sympathetic system and hypertension. Am J Hypertens 2000 Jun;13(6 Pt 2):99S-105S.
Functional role of renal afferents. Physiol Rev 1991 Jul;71(3):659-682.
Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens 2012 Nov;30(11):2230-2239.
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009 Apr;373(9671):1275-1281.
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010 Dec;376(9756):1903-1909.
Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014 Jul;35(26):1752-1759.
Renal denervation in treatment-resistant hypertension: a reappraisal. Curr Opin Pharmacol 2015 Apr;21:48-52.
SYMPLICITY HTN-3 Investigators; A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 Apr;370(15):1393-1401.
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015 Jan;36(4):219-227.
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015 May;385(9981):1957-1965.
First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015 Apr;65(4):766-774.
Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system. Euro Intervention 2014 May;10(1):157-165.
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol 2014 Feb;103(2):117-124.
Renal artery sympathetic denervation: observations from the UK experience. Clin Res Cardiol 2016 Jun;105(6):544-552.
Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre-and post-procedural comparison with the Simplicity catheter system and the Enlig HTN multi-electrode renal denervation catheter. Eur Heart J 2013 Jul;34(28):2141-2148.
Multimodality intra-arterial imaging assessment of the vascular trauma induced by balloon-based and nonballoon-based renal denervation systems. Circ Cardiovasc Interv 2015 Jul;8(7):e002474.
Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension. Heart 2015 Jan;101(1):10-16.
Renal denervation therapy for hypertension: pathways for moving development forward. J Am Soc Hypertens 2015 May;9(5):341-350.
Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. JACC Cardiovasc Interv 2016 Mar;9(6):589-598.
A novel non-vascular system to treat resistant hypertension. Euro Intervention 2013;9(1):135-139.
The autonomic nervous system and hypertension. Circ Res 2014 May;114(11):1804-1814.
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010 Oct;56(15):1254-1258.
Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009 Sep;54(3):530-536.
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 2011 Aug;58(7):765-773.
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012 Mar-Apr;6(2):152-158.
Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 2015 Jan;65(1):187-192.
Baroreflex activation therapy in hypertension. J Hum Hypertens 2014 Aug;28(8):469-474.
Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012 Jul-Aug;6(4):270-276.
Impact of baroreflex activation therapy on renal function—a pilot study. Am J Nephrol 2014 Nov;40(4):371-380.
Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015 Jun;3(6):487-496.
The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 2013 Jan;61(1):5-13.
Immediate effects of bilateral carotid body resection on total respiratory resistance and compliance in humans. Adv Exp Med Biol 2004;551:15-21.
Unilateral carotid body resection as an anti-hypertensive strategy: a proof of principle study in resistant hypertensive patients. J Hum Hypertens 2015 Oct;29(10):625.
The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. Catheter Cardiovasc Interv 2015 Apr;85(5):880-886.
Arteriovenous anastomosis: is this the way to control hypertension? Hypertension 2014 Jul;64(1):6-12.
Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation. Curr Hypertens Rep 2015 Sep;17(9):585.
An arteriovenous fistula increases exercise capacity in patients with COPD. Chest 2010 Jul;138(1):52-58.
Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg 2014 Apr;59(4):1078-1083.
Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 2015;385(9978):1634-1641.
Central arteriovenous anastomosis for hypertension: it is not all about sympathomodulation. Future Cardiol 2015 Sep;11(5):503-506.
Ventrolateral medullary lesions block the antino-ciceptive and cardiovascular responses elicited by stimulating the dorsal periaqueductal grey matter in rats. Pain 1985 Mar;21(3):241-252.
Viscerotopic organization of neurons subserving hypotensive reactions within the midbrain periaqueductal grey: a correlative functional and anatomical study. Brain Res 1991 Feb;541(2):206-215.
Deep brain stimulation relieves refractory hypertension. Neurology 2011 Jan;76(4):405-407.
Deep brain stimulation of the periaqueductal grey induces vasodilation in humans. Hypertension 2011 May;57(5):e24-25.
Differentiated baroreflex modulation of sympathetic nerve activity during deep brain stimulation in humans. Hypertension 2014 May;63(5):1000-1010.
Electroacu-puncture modulation of reflex hypertension in rats: role of cholecystokinin octapeptide. Am J Physiol Regul Integr Comp Physiol 2013 Aug;305(4):R404-413.
Long-lasting reduction of blood pressure by electroacupuncture in patients with hypertension: randomized controlled trial. Med Acupunct 2015 Aug;27(4):253-266.
Intermittent electrical stimulation of the right cervical vagus nerve in salt-sensitive hypertensive rats: effects on blood pressure, arrhythmias, and ventricular electrophysiology. Physiol Rep 2015 Aug;3(8).
Blood pressure control with selective vagal nerve stimulation and minimal side effects. J Neural Eng 2014 Jun;11(3):036011.
Effect of selective vagal nerve stimulation on blood pressure, heart rate and respiratory rate in rats under metoprolol medication. Hypertens Res 2016 Feb;39(2):79-87.
Haemodynamic responses to selective vagal nerve stimulation under enalapril medication in rats. PLoS One 2016 Jan;11(1):e0147045.
Frequency dependent effect of selective biphasic left vagus nerve stimulation on heart rate and arterial pressure. Signa Vitae 2012 Oct;7(2):63-68.
Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988 Jan;11(1):3-20.
Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2014 Mar;28(3):150-156.
Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015 Jan;65(1):193-199.